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A 58-year-old woman was admitted to our hospital with fever, malaise and weight loss for 
more than 18 months. She has been treated with antibiotics for pneumonia twice, but fever 
and fatigue recurred. She received a kidney transplant due to chronic pyelonephritis 20 years 
ago. Induction therapy was performed with cyclosporine, mycophenolat mofetil and 
corticosteroids. Therapy with corticosteroids was withdrawn in 2010. She was seronegative 
for Epstein-barr virus (EBV) and received a kidney from a seronegative donor. The post-
transplant course was unremarkable without any episodes of rejection. The physical 
examination unveiled several enlarged cervical, left-sided supraclavicular and axillary lymph 
nodes. Her former left-sided arteriovenous (av) fistula was thrombotic since a while, but she 
reported a sudden enlargement with signs of inflammation. Laboratory findings revealed a 
stable renal function (estimated glomerular filtration rate 65 mL/min), anaemia and 
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thrombocytopenia, a slightly elevated C-reactive protein, while leukocytes were within the 
normal range. LDH was increased (516 U/L, normal range < 214 U/L). EBV DNA was PCR-
detectable in the serum; the quantification revealed a copy number of 9,870/mL. A positron 
emission tomography/computed tomography (PET/CT) detected fluorodeoxyglucose (FDG) 
enhancement in the mass of the AV fistula and in several enlarged axillary lymph nodes 
(Fig. 1 A, B). Surgical resection of an aneurysmatic brachial artery with a soft tissue mass 
(6.5 x 5.5 x 3.0 cm) underwent histological examination. A dense infiltrate consisting of 
diffusely growing large, occasionally multinucleated, lymphoid blasts, that expressed CD30 
and the cytotoxic molecule perforin as well as several blasts with CD15 and CD3 expression 
led to the diagnosis of a monomorphous T-cell PTLD with features of an anaplastic large T-
cell lymphoma (ALCL; Fig 1 C, D). The tumour cells did not express the anaplastic 
lymphoma kinase and specific markers of a latent EBV infection were undetectable.  
A CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone)-like 
polychemotherapy remains the standard of care for T-cell lymphoma, although often 
producing disappointing results in this heterogeneous entity1. Moreover, regarding CD20+ B-
cell PTLD, CHOP-based induction therapy might be effective, but comes with an 
unacceptably high treatment-related mortality in this particular group of immunocompromised 
patients2. Therefore, a B-cell PTLD-tailored induction protocol was introduced consisting of 
four initial courses of single-agent anti-CD20 Rituximab immunotherapy followed by another 
four cycles of a CHOP regimen, achieving excellent long-term survival, largely attributable to 
reduced toxicity, in Rituximab responders3. Given the frail overall condition of our patient at 
initial presentation, rendering her ineligible for a systemic CHOP-like chemotherapy, we 
considered here – in analogy to the anti-CD20 Rituximab mono-strategy against B-cell PTLD 
– an anti-CD30 Brentuximab vedotin (BV) mono-strategy against her T-cell PTLD.  
 
3 
 
BV is currently approved for the treatment of patients with relapsed/refractory Hodgkin’s 
lymphoma after failure of a high-dose chemotherapy with autologous stem-cell support or two 
previous lines of polychemotherapy in transplant-ineligible patients, and for patients with 
systemic ALCL after at least one preceding multi-agent chemotherapy. We found off-label 
use of BV a particularly appealing option for our patient, since BV is actually an antibody-
drug conjugate, designed to deliver relatively high doses of the cytotoxic moiety selectively to 
their cellular targets while producing limited systemic toxicity. Moreover, BV, unlike 
Rituximab, does not rely on immune-mediated effector principles (like antibody-dependent 
cellular cytotoxicity) that may not be fully operational in immunosuppressed recipients of 
solid organ transplants.  
 Three courses of BV (1.8 mg/kg bodyweight) were administered every three week. 
Unfortunately, she developed severe polyneuropathy in her lower extremities, a common side 
effect of BV therapy, leading to the cessation of BV therapy. Despite no histological evidence 
of B-cell lymphoproliferation, but due to repetitively positive PCR analyses for EBV DNA in 
the serum, additional Rituximab therapy (375mg/m2) was given twice, each dose 10 to 12 
days after the first and second cycle of BV, resulting in a negative EBV test after four weeks. 
Studies about the efficacy of BV monotherapy or even in combination with Rituximab are 
limited. Very recently, encouraging  phase 2 results about the use of single-agent BV in 
patients with relapsed or refractory CD30+ diffuse large B-cell lymphoma as well as 
cutaneous T-cell lymphoma and ALCL-related lymphoproliferative disorders were 
reported 4,5. To the best of our knowledge, our case represents the first administration of BV 
monotherapy in the initial treatment of a CD30+ PTLD, which manifested at an unusual site in 
an unused av fistula. PTLD represent a major complication after solid organ or hematopoietic 
stem cell transplantation. Approximately 85% of PTLDs are of B-cell origin, while the 
proportion of T-cell PTLD is only 10-15%. The rate of EBV association is about 50% overall, 
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with less than 10% in the late cases3. Despite the – expected – non-detectability of EBV 
components in the T-cellular ALCL population, we cannot exclude a co-founding, T-cell 
proliferation- and –transformation-promoting role of adjacent EBV-positive B-cells. In 
general, the vast majority of PTLD cases has been found to be CD30+ 6, although testing for 
CD30 immunoreactivity is not mandatory in the approved BV indications. Concomitant use of 
corticosteroids should be avoided, since it may result in the rapid downregulation of the CD30 
target. In the case of our patient, a follow up PET/CT 6 months after the first diagnostic PET 
(Fig 1 E, F) showed a complete remission. Future follow-up will be based on clinical 
examination, CT scans and potentially PET7. A very recent PET/CT after 2 more years still 
showed no signs of recurrence, and our patient is in good health.  
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Figure legends 
 
Figure 1  
PET/ CT detected FDG enhancement in the mass of the AV fistula, and furthermore in several 
enlarged axillar lymph nodes (A, showing the maximum intensity projection; B, CT showing 
the mass lesion in the left cubital fossa). Follow up FDG PET/ CT six months later showed no 
more evidence of significantly increased FDG uptake (E, F).  
Histological analysis of the dissected tumour shows a dense infiltrate which consists of sheets 
of large lymphoid blasts that are occasionally multinucleated (C, haematoxylin and eosin stain 
x40). All blasts express CD30 (D, immunostains using monoclonal anti-CD30 antibody clone 
BerH2 x40).  
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Figure
 
